Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)Genotypic resistance profiles of HIV-2-treated patients in West Africa.Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infectionsDiscordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent.National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.Twelve months of routine HIV screening in 6 emergency departments in the Paris area: results from the ANRS URDEP study.Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypesPredictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patientsTransmitted drug resistance in French HIV-2-infected patients.Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravirDrug resistance mutations in HIV-1.In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.Update of the drug resistance mutations in HIV-1: 2007.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.Rapid discrimination between human immunodeficiency virus type 2 groups A and B by real-time PCR.Update of the drug resistance mutations in HIV-1: December 2010.HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe.Interpretation of antibodies reacting solely with human retroviral core proteins in western equatorial Africa.Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism.Tropism distribution among antiretroviral-naive HIV-2-infected patients.Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG.High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients.Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).No association between GB virus C infection and disease progression in HIV-2-infected patients from the French ANRS HIV-2 cohort.Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification.Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.
P50
Q22242256-417BD05A-6FBF-4D09-8C43-29D9349A8D1AQ33954546-54B022BA-AD2C-4BBC-B479-DB024C9AFED2Q34108713-90797557-C225-41B4-8C86-D0ADE1D909E7Q34199460-39700491-332A-4116-A5D9-1A96A853C8B1Q34352000-0E797226-ADA5-4E0D-8A0E-9A9286CB2ABEQ34353387-9CE160EC-3CCC-4E90-B574-1847F11C0CBAQ34387349-E2CCF540-143D-4F71-A95A-4057D6134B17Q34441451-D04B5A5A-16EB-4074-85B5-C356FF761EC7Q34562253-0553D83D-3172-4C4D-9BF5-1A643160F226Q34563005-3FECAB51-885F-402D-9DFE-36976FE919F6Q34634839-CEE8A913-47EA-4EDF-B5AE-6611EEB2DCFFQ34675595-A98DCCD3-1F3E-4FE7-81AB-39D6043B7FFBQ34737268-000347B9-3936-44C3-81B7-287887F1CB95Q35629340-A0B0C640-8529-476C-980D-53DC21DD689BQ35666480-3CAD4C89-D210-47F5-A7C0-A3632F8221F6Q35738681-FCC7D95D-F906-4DE9-86EC-0517F7E932F1Q36538702-903DA8AE-F0C8-41F1-8E9B-012ABD528FD5Q36880577-0103BFF5-77B2-4B02-8B63-C300C5B2FBDEQ36919747-04353A96-37B8-4BCC-B823-69F4627F22B2Q37189622-24FD9E70-8193-4F87-B2E6-9DB6D6E00B98Q37621435-A47DF1A1-5364-44E7-9F4F-5FB87B7BD606Q37703311-CE751429-2DDF-47BF-BE23-558D79278F7AQ37829827-B25F40DB-9AF7-462A-A728-2C545B5C0CB8Q38083487-1641582A-EE00-4FAF-9E40-C75F733EEC57Q38969080-5FBA6F04-86D3-4F38-8806-F0A176A9426FQ39433148-2708D83A-F5E5-4480-AF27-6BFFA48618AAQ39480583-2CF4846C-CC48-4B4D-BD28-B6385E75C0BFQ39562906-C8128E48-8339-4C03-889B-C99F60E71AAAQ39626666-6EC9C5A8-9C7B-46B6-9858-024AD2326C2DQ41222576-244504AD-A2D0-4650-8E37-D9FA940DFE39Q41723416-90192798-2EC3-4821-B38A-4ADE1AFACC59Q41775697-19D35515-98FC-40B9-AF8C-CC83262CDBE6Q42211136-180D6A1C-8444-41CF-8F06-F9BFE725976FQ42276937-58CE3BA5-536E-43AD-97E1-E610F600BE80Q42912922-BB6447E0-13FD-45F7-8353-86AF0BA315A9Q42923014-33897291-7EEF-44B4-8867-1B8C51CAFA14Q42929822-483A2C6B-8620-482C-89DF-759D6F797CDEQ42999361-EF0A2A66-F0D3-4029-B200-6EC899C96BE8Q43218155-D832314C-65A4-4013-8898-6A14258276D6Q43253153-6AEAC679-30D8-4042-A44D-AEE932C92C96
P50
description
Frans virologe
@nl
French virologist involved in discovery of HIV
@en
French virologist involved in discovery of HIV
@en-gb
französisch Virologin
@de
virologue française, participante à la découverte du VIH
@fr
viróloga francesa
@ast
name
Françoise Brun-Vézinet
@ast
Françoise Brun-Vézinet
@ca
Françoise Brun-Vézinet
@de
Françoise Brun-Vézinet
@en
Françoise Brun-Vézinet
@en-gb
Françoise Brun-Vézinet
@es
Françoise Brun-Vézinet
@fr
Françoise Brun-Vézinet
@nl
Françoise Brun-Vézinet
@pt
Françoise Brun-Vézinet
@sl
type
label
Françoise Brun-Vézinet
@ast
Françoise Brun-Vézinet
@ca
Françoise Brun-Vézinet
@de
Françoise Brun-Vézinet
@en
Françoise Brun-Vézinet
@en-gb
Françoise Brun-Vézinet
@es
Françoise Brun-Vézinet
@fr
Françoise Brun-Vézinet
@nl
Françoise Brun-Vézinet
@pt
Françoise Brun-Vézinet
@sl
altLabel
Françoise Brun-Vezinet
@fr
prefLabel
Françoise Brun-Vézinet
@ast
Françoise Brun-Vézinet
@ca
Françoise Brun-Vézinet
@de
Françoise Brun-Vézinet
@en
Françoise Brun-Vézinet
@en-gb
Françoise Brun-Vézinet
@es
Françoise Brun-Vézinet
@fr
Françoise Brun-Vézinet
@nl
Françoise Brun-Vézinet
@pt
Françoise Brun-Vézinet
@sl
P106
P21
P27
P31
P569
1953-01-01T00:00:00Z